Literature DB >> 10794485

Reproducibility studies and interlaboratory concordance for androgen assays in female plasma.

T R Fears1, R G Ziegler, J L Donaldson, R T Falk, R N Hoover, F Z Stanczyk, J B Vaught, M H Gail.   

Abstract

We conducted studies to determine the magnitude and sources of variability in androgen assay results and to identify laboratories capable of performing such assays for large epidemiological studies. We studied androstanediol (ADIOL), androstanediol glucuronide (ADIOL G), androstenedione (ADION), androsterone glucuronide (ANDRO G), androsterone sulfate (ANDRO S), dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA S), dihydrotestosterone (DHT), and testosterone (TESTO). A single sample of plasma was obtained from five postmenopausal women, five premenopausal women in the midfollicular phase of the menstrual cycle, and five women in the midluteal phase, divided into aliquots, and stored at -70 degrees. Four sets of two coded aliquots from each woman were then sent to participating labs for analysis at monthly intervals over 4 months. Using the logarithm of assay measurements, we estimated the components of variance and three measures of reproducibility. The usual coefficient of variation is a function of the components that are under the control of the laboratory. The intraclass correlation between measurements for a given individual is the proportion of the total variability that is associated with individuals. The minimum detectable relative difference is important to evaluate study feasibility. Results suggest that a single sample of ADIOL G, DHEA, DHEA S, and ANDRO G (with two lab replicates per sample) can be used to discriminate reliably among women in a given menstrual phase or menopausal status. The results for DHT, TESTO, ADION, and ANDRO S are more problematic and suggest that the present measurement techniques should be used with care, especially with midluteal phase women. The results for ADIOL suggest that this assay is not yet ready for use in epidemiological studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10794485

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  24 in total

Review 1.  Importance of hypogonadism and testosterone replacement therapy in current urologic practice: a review.

Authors:  Wayne J G Hellstrom; Darius Paduch; Craig F Donatucci
Journal:  Int Urol Nephrol       Date:  2010-12-09       Impact factor: 2.370

2.  Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Authors:  Stephanie J Weinstein; Mark P Purdue; Stephanie A Smith-Warner; Alison M Mondul; Amanda Black; Jiyoung Ahn; Wen-Yi Huang; Ronald L Horst; William Kopp; Helen Rager; Regina G Ziegler; Demetrius Albanes
Journal:  Int J Cancer       Date:  2014-09-02       Impact factor: 7.396

3.  Vitamin D-binding protein and pancreatic cancer: a nested case-control study.

Authors:  Marina R Piper; D Michal Freedman; Kim Robien; William Kopp; Helen Rager; Ronald L Horst; Rachael Z Stolzenberg-Solomon
Journal:  Am J Clin Nutr       Date:  2015-04-22       Impact factor: 7.045

4.  Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers.

Authors:  Rachael Z Stolzenberg-Solomon; Stephanie Weinstein; Michael Pollak; Yuzhen Tao; Philip R Taylor; Jarmo Virtamo; Demetrius Albanes
Journal:  Am J Epidemiol       Date:  2008-09-18       Impact factor: 4.897

5.  Circulating 25-hydroxyvitamin D up to 3 decades prior to diagnosis in relation to overall and organ-specific cancer survival.

Authors:  Stephanie J Weinstein; Alison M Mondul; Kai Yu; Tracy M Layne; Christian C Abnet; Neal D Freedman; Racheal Z Stolzenberg-Solomon; Unhee Lim; Mitchell H Gail; Demetrius Albanes
Journal:  Eur J Epidemiol       Date:  2018-08-02       Impact factor: 8.082

6.  Circulating insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 levels and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort.

Authors:  Catherine Schairer; Catherine A McCarty; Claudine Isaacs; Laura Y Sue; Michael N Pollak; Christine D Berg; Regina G Ziegler
Journal:  Horm Cancer       Date:  2010-04       Impact factor: 3.869

7.  Serum C-reactive protein and risk of pancreatic cancer in two nested, case-control studies.

Authors:  Jason B Douglas; Debra T Silverman; Stephanie J Weinstein; Barry I Graubard; Michael N Pollak; Yuzhen Tao; Jarmo Virtamo; Demetrius Albanes; Rachael Z Stolzenberg-Solomon
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-12-20       Impact factor: 4.254

8.  Serum vitamin D, vitamin D binding protein, and lung cancer survival.

Authors:  Gabriella M Anic; Stephanie J Weinstein; Alison M Mondul; Satu Männistö; Demetrius Albanes
Journal:  Lung Cancer       Date:  2014-10-20       Impact factor: 5.705

9.  One-carbon metabolism biomarkers and risk of colon and rectal cancers.

Authors:  Stephanie J Weinstein; Demetrius Albanes; Jacob Selhub; Barry Graubard; Unhee Lim; Philip R Taylor; Jarmo Virtamo; Rachael Stolzenberg-Solomon
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

10.  Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.

Authors:  Rachael Z Stolzenberg-Solomon; Eric J Jacobs; Alan A Arslan; Dai Qi; Alpa V Patel; Kathy J Helzlsouer; Stephanie J Weinstein; Marjorie L McCullough; Mark P Purdue; Xiao-Ou Shu; Kirk Snyder; Jarmo Virtamo; Lynn R Wilkins; Kai Yu; Anne Zeleniuch-Jacquotte; Wei Zheng; Demetrius Albanes; Qiuyin Cai; Chinonye Harvey; Richard Hayes; Sandra Clipp; Ronald L Horst; Lonn Irish; Karen Koenig; Loic Le Marchand; Laurence N Kolonel
Journal:  Am J Epidemiol       Date:  2010-06-18       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.